Both human B cell hybridoma technology and convalescent plasma therapy are promising immunological tools for therapeutic interventions. Here we propose using antibody producing B cells from convalescent SARS-CoV2 patients for developing human B cell hybridomas, and a combination of monoclonal antibodies against multiple immunogenic targets of SARS-CoV-2 spike protein might deliver an antibody cocktail for long-lasting therapeutic targeting.

中文翻译：

---

康复期人B细胞杂交瘤衍生的多单克隆（非多克隆）抗体可能比单靶标单克隆抗体更好的治疗选择。

人类B细胞杂交瘤技术和恢复性血浆疗法都是用于治疗干预的有前途的免疫学工具。在这里，我们建议使用来自恢复期SARS-CoV2患者的产生抗体的B细胞来发展人类B细胞杂交瘤，针对多种SARS-CoV-2刺突蛋白免疫原性靶标的单克隆抗体的组合可能会为长期治疗靶向提供抗体混合物。